Guardant Health, Inc. (NASDAQ:GH) Receives $40.60 Consensus PT from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have been given an average rating of “Buy” by the fifteen analysts that are covering the company, MarketBeat.com reports. Fifteen analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $40.60.

Several equities research analysts recently issued reports on the stock. Sanford C. Bernstein decreased their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Leerink Partners decreased their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, The Goldman Sachs Group raised their price objective on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Insider Activity at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the sale, the director now owns 7,648 shares in the company, valued at $228,675.20. This represents a 27.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the sale, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. This represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,432 shares of company stock worth $175,423 over the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

Hedge funds have recently modified their holdings of the stock. Lord Abbett & CO. LLC bought a new stake in Guardant Health in the 3rd quarter valued at about $15,624,000. Exome Asset Management LLC grew its stake in Guardant Health by 13.7% in the third quarter. Exome Asset Management LLC now owns 89,800 shares of the company’s stock valued at $2,060,000 after acquiring an additional 10,800 shares during the period. Geode Capital Management LLC increased its holdings in shares of Guardant Health by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after acquiring an additional 29,686 shares in the last quarter. Pier Capital LLC raised its position in shares of Guardant Health by 36.7% during the third quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock worth $3,634,000 after purchasing an additional 42,575 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of Guardant Health by 188.6% in the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock worth $232,325,000 after purchasing an additional 6,618,785 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Up 0.3 %

Shares of GH stock opened at $36.71 on Friday. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $38.53. The stock’s fifty day moving average price is $32.61 and its two-hundred day moving average price is $28.65. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22. The company has a market cap of $4.54 billion, a PE ratio of -8.66 and a beta of 1.28.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. During the same quarter in the prior year, the company earned ($0.73) earnings per share. Guardant Health’s quarterly revenue was up 33.9% compared to the same quarter last year. Equities analysts predict that Guardant Health will post -3.44 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.